Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept for cerebral perfusion and oxygenation in non-transfusion-dependent beta-thalassemia
NL-OMON60807Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of luspatercept in beta thalassemia and anaemia, sponsored by Amsterdam University Medical Center. Primary endpoint: Cerebral metabolic rate of oxygen (CMRO2). Started Jul 2024; status: recruiting.
02
Drugs
luspatercept
03
Conditions
beta thalassemiaanaemia
Beyond the preview
Go deeper on NL-OMON60807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60807.